Trials / Completed
CompletedNCT02906397
Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and tolerability of galunisertib when combined with Stereotactic Body Radiotherapy (SBRT) (hypofractionated radiation).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galunisertib 150mg by mouth twice a day | on days 1-14 of 28 day cycles |
| RADIATION | Stereotactic Body Radiotherapy (SBRT) | 18GY delivered in one fraction between C1D15 and C1D28 |
Timeline
- Start date
- 2017-03-30
- Primary completion
- 2021-07-21
- Completion
- 2021-07-21
- First posted
- 2016-09-20
- Last updated
- 2022-03-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02906397. Inclusion in this directory is not an endorsement.